Table 2:

Efficacy Analysis by Treatment Groups^*

	Group 1 n=14	Group 2 n=29	Group 3 n=28	Group 4 n=30
CBR, % 95% CI	7% (0.2–34%)	17 % (5.8–36%)	21% (8.3–41%)	23% (9.9–42%)
Median PFS, months 95% CI	3.5 (1.2–14)	2.6 (2–4)	3.5 (2.6–4.8)	4.9 (2.7–6.9)
PFS rate at 6 months 95% CI	40% (19–60%)	23% (9.5–39%)	21% (8.7–38%)	43% (26–60%)
DOR, months 95% CI	6.5 (2.2–NE)	5.6 (2.1–15)	3.4 (2.4–8.3)	3.2 (2.3–6.4)
Median OS, years 95% CI	2.9 (1.3–5.7)	2.5 (2–3)	4.1 (2.9–5.3)	4.5 (3.4–6.9)
3-year OS rate, % 95% CI	48% (20–71%)	32% (15–51%)	67% (47–82%)	77% (57–88%)

^*group is defined as the number of prior lines of treatment: (1) one prior line of therapy, (2) two prior lines of therapy, (3) three prior lines of therapy, and (4) ≥ four lines of therapy.

CBR, clinical benefit rate; PFS, progression-free survival; DOR, duration of response; OS, overall survival; CI, confidence interval; NE, not estimable